The Autoimmune Gastrointestinal Dysmotility (AGID) Market is emerging as a niche yet critical segment within the broader gastrointestinal and neurology therapeutics landscape. AGID is a rare, often underdiagnosed disorder where the body's immune system attacks the enteric nervous system, leading to impaired gut motility. Symptoms such as severe constipation, gastroparesis,...